Oliver H KrÃ¤mer

List of Publications by Year
in descending order

114 papers	5,411 citations	94381 37 h-index	88593 70 g-index
118 all docs	118 docs citations	118 times ranked	8159 citing authors

#	Article	IF	Citations
1	The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil. Cell Biology and Toxicology, 2023, 39, 2401-2419.	2.4	6
2	Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Archives of Toxicology, 2022, 96, 177-193.	1.9	10
3	Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells. Cell Chemical Biology, 2022, 29, 398-411.e4.	2.5	9
4	HDAC2 Facilitates Pancreatic Cancer Metastasis. Cancer Research, 2022, 82, 695-707.	0.4	19
5	Microsatellite Status and Î²BÎ± Expression Levels Predict Sensitivity to Pharmaceutical Curcumin in Colorectal Cancer Cells. Cancers, 2022, 14, 1032.	1.7	4
6	Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells. European Journal of Medicinal Chemistry, 2022, 234, 114272.	2.6	15
7	Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity. International Journal of Molecular Sciences, 2022, 23, 369.	1.8	28
8	News and views. Archives of Toxicology, 2022, 96, 2143-2144.	1.9	1
9	Singleâ€cell profiling guided combination therapy of câ€Fos and histone deacetylase inhibitors in diffuse large Bâ€cell lymphoma. Clinical and Translational Medicine, 2022, 12, .	1.7	3
10	Global metabolic alterations in colorectal cancer cells during irinotecan-induced DNA replication stress. Cancer & Metabolism, 2022, 10, .	2.4	8
11	RNA interference protocol to silence oncogenic drivers in leukemia cell lines. STAR Protocols, 2022, 3, 101512.	0.5	2
12	Structural Insights into the Interaction of Heme with Protein Tyrosine Kinase JAK2**. ChemBioChem, 2021, 22, 861-864.	1.3	5
13	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. Journal of Medicinal Chemistry, 2021, 64, 8486-8509.	2.9	28
14	Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition. Cancers, 2021, 13, 3464.	1.7	5
15	Mechanistic insights into p53â€regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells. Molecular Oncology, 2021, 15, 3404-3429.	2.1	15
16	Novel insight into mechanisms for ATR activation by chromatin structures. Archives of Toxicology, 2021, 95, 3433-3434.	1.9	0
17	STAT1 N-terminal domain discriminatively controls type I and type II IFN signaling. Cytokine, 2021, 144, 155552.	1.4	7
18	Important role of Nfkb2 in the KrasG12D-driven carcinogenesis in the pancreas. Pancreatology, 2021, 21, 912-919.	0.5	3

#	Article	IF	Citations
19	Class 1 Histone Deacetylases and Ataxia-Telangiectasia Mutated Kinase Control the Survival of Murine Pancreatic Cancer Cells upon dNTP Depletion. Cells, 2021, 10, 2520.	1.8	6
20	The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188453.	3.3	19
21	Targeting the ubiquitinâ€proteasome system in a pancreatic cancer subtype with hyperactive MYC. Molecular Oncology, 2020, 14, 3048-3064.	2.1	13
22	Impact of the STAT1 N-terminal domain for fibrosarcoma cell responses to É£-irradiation. Experimental Results, 2020, 1, .	0.2	1
23	A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia. European Journal of Medicinal Chemistry, 2020, 193, 112232.	2.6	8
24	Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes. Journal of Cancer Research and Clinical Oncology, 2020, 146, 343-356.	1.2	37
25	HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of Î²-catenin, MYC, and WT1. Cancers, 2019, 11, 1436.	1.7	27
26	PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1. Scientific Reports, 2019, 9, 8755.	1.6	16
27	DNA replication dynamics of vole genome and its epigenetic regulation. Epigenetics and Chromatin, 2019, 12, 18.	1.8	5
28	Human platelet lysate as validated replacement for animal serum to assess chemosensitivity. ALTEX: Alternatives To Animal Experimentation, 2019, 36, 277-288.	0.9	12
29	HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130. Nature Communications, 2018, 9, 764.	5.8	58
30	Design and biological evaluation of tetrahydro-Î²-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors. European Journal of Medicinal Chemistry, 2018, 152, 329-357.	2.6	34
31	A p300 and SIRT1 Regulated Acetylation Switch of C/EBPÎ± Controls Mitochondrial Function. Cell Reports, 2018, 22, 497-511.	2.9	45
32	MTOR inhibitor-based combination therapies for pancreatic cancer. British Journal of Cancer, 2018, 118, 366-377.	2.9	35
33	Loss of Wilms tumor 1 protein is a marker for apoptosis in response to replicative stress in leukemic cells. Archives of Toxicology, 2018, 92, 2119-2135.	1.9	9
34	Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 3454-3477.	2.9	56
35	PNUTS at the crossroads of tumorigenesis and metastasis formation. Journal of Thoracic Disease, 2018, 10, 560-563.	0.6	5
36	Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. PLoS ONE, 2018, 13, e0207915.	1.1	38

#	Article	IF	Citations
37	STAT1â€'HDAC4 signaling induces epithelialâ€'mesenchymal transition and sphere formation of cancer cells overexpressing the oncogene, CUG2. Oncology Reports, 2018, 40, 2619-2627.	1.2	26
38	The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells. Archives of Toxicology, 2018, 92, 2227-2243.	1.9	57
39	Survivin antagonizes chemotherapy-induced cell death of colorectal cancer cells. Oncotarget, 2018, 9, 27835-27850.	0.8	19
40	Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line. World Journal of Gastroenterology, 2018, 24, 3749-3759.	1.4	11
41	Establishment, functional and genetic characterization of three novel patient-derived rectal cancer cell lines. World Journal of Gastroenterology, 2018, 24, 4880-4892.	1.4	7
42	Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 29-39.	3.3	43
43	The interplay between histone deacetylases and rho kinases is important for cancer and neurodegeneration. Cytokine and Growth Factor Reviews, 2017, 37, 29-45.	3.2	6
44	HSP90 is necessary for the ACK1-dependent phosphorylation of STAT1 and STAT3. Cellular Signalling, 2017, 39, 9-17.	1.7	32
45	Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling. Cellular Oncology (Dordrecht), 2017, 40, 549-561.	2.1	28
46	Interstrand Crosslink Repair as a Target for HDAC Inhibition. Trends in Pharmacological Sciences, 2017, 38, 822-836.	4.0	47
47	Detection of Autophagy Induction After HDAC Inhibitor Treatment in Leukemic Cells. Methods in Molecular Biology, 2017, 1510, 3-10.	0.4	3
48	Class I histone deacetylases regulate p53/NF-ÎºB crosstalk in cancer cells. Cellular Signalling, 2017, 29, 218-225.	1.7	41
49	Analyzing the Impact of Pan- and Class-Specific HDACi on Differentiation-Associated Factors. Methods in Molecular Biology, 2017, 1510, 375-385.	0.4	2
50	Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells. Archives of Toxicology, 2017, 91, 2191-2208.	1.9	26
51	SUMOylation regulates the intracellular fate of ZO-2. Cellular and Molecular Life Sciences, 2017, 74, 373-392.	2.4	18
52	How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot. Methods in Molecular Biology, 2017, 1510, 355-364.	0.4	21
53	Histone deacetylase inhibitors induce proteolysis of activated CDC42-associated kinase-1 in leukemic cells. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2263-2273.	1.2	19
54	Concepts to Target MYC in Pancreatic Cancer. Molecular Cancer Therapeutics, 2016, 15, 1792-1798.	1.9	64

#	Article	IF	Citations
55	Establishment and characterization of HROC69â€‰â€“â€‰a CrohnÂ´s related colonic carcinoma cell line and its matched patient-derived xenograft. Scientific Reports, 2016, 6, 24671.	1.6	12
56	Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance. Cancer Research, 2016, 76, 3067-3077.	0.4	75
57	Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewingâ€™s sarcoma cells: resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity. Journal of Cancer Research and Clinical Oncology, 2016, 142, 17-26.	1.2	19
58	Pasteurella multocida toxin- induced osteoclastogenesis requires mTOR activation. Cell Communication and Signaling, 2015, 13, 40.	2.7	11
59	Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM. Oncotarget, 2015, 6, 33755-33768.	0.8	42
60	Sumoylation of HDAC2 promotes NF-ÎºB-dependent gene expression. Oncotarget, 2015, 6, 7123-7135.	0.8	40
61	JAK1/STAT3 activation directly inhibits IL-12 production in dendritic cells by preventing CDK9/P-TEFb recruitment to the p35 promoter. Biochemical Pharmacology, 2015, 96, 52-64.	2.0	18
62	The inducible E3 ubiquitin ligases SIAH1 and SIAH2 perform critical roles in breast and prostate cancers. Cytokine and Growth Factor Reviews, 2015, 26, 405-413.	3.2	23
63	Fly versus man: evolutionary impairment of nucleolar targeting affects the degradome of Drosophila's Taspase1. FASEB Journal, 2015, 29, 1973-1985.	0.2	9
64	STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nature Communications, 2015, 6, 7736.	5.8	136
65	RETRA exerts anticancer activity in Ewingâ€™s sarcoma cells independent of their TP53 status. European Journal of Cancer, 2015, 51, 841-851.	1.3	15
66	Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. Thorax, 2015, 70, 1022-1032.	2.7	106
67	Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells. Oncotarget, 2015, 6, 5354-5368.	0.8	12
68	TAK1 and IKK2, novel mediators of SCF-induced signaling and potential targets for c-Kit-driven diseases. Oncotarget, 2015, 6, 28833-28850.	0.8	13
69	Caspase-3 and Caspase-6 cleave STAT1 in leukemic cells. Oncotarget, 2014, 5, 2305-2317.	0.8	11
70	MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib. Nucleic Acids Research, 2014, 42, 10433-10447.	6.5	58
71	Arginine residues within the DNA binding domain of STAT3 promote intracellular shuttling and phosphorylation of STAT3. Cellular Signalling, 2014, 26, 1698-1706.	1.7	8
72	Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 524-538.	3.3	57

#	Article	IF	Citations
73	Drugging the HDAC6â€“HSP90 interplay in malignant cells. Trends in Pharmacological Sciences, 2014, 35, 501-509.	4.0	110
74	Survivin and YM155: How faithful is the liaison?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 202-220.	3.3	90
75	Caspase-8-mediated PAR-4 cleavage is required for TNFÎ±-induced apoptosis. Oncotarget, 2014, 5, 2988-2998.	0.8	30
76	SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells. Oncotarget, 2014, 5, 3184-3196.	0.8	31
77	WT1 Protects Leukemic Cells from Cytotoxic Replicative Stress. Blood, 2014, 124, 880-880.	0.6	0
78	Interferon alpha-armed nanoparticles trigger rapid and sustained STAT1-dependent anti-viral cellular responses. Cellular Signalling, 2013, 25, 989-998.	1.7	5
79	Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP) and organ donors. Journal of Proteomics, 2013, 85, 109-128.	1.2	64
80	Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53â€independent pancreatic cancer cell death. International Journal of Cancer, 2013, 132, 2248-2257.	2.3	26
81	Acetylation of Endogenous STAT Proteins. Methods in Molecular Biology, 2013, 967, 167-178.	0.4	9
82	STAT5 acetylation. Jak-stat, 2013, 2, e26102.	2.2	18
83	Allosteric inhibition of Taspase1â€²s pathobiological activity by enforced dimerizationin vivo. FASEB Journal, 2012, 26, 3421-3429.	0.2	22
84	A ZEB1-HDAC pathway enters the epithelial to mesenchymal transition world in pancreatic cancer: Figure 1. Gut, 2012, 61, 329-330.	6.1	15
85	PML promotes MHC class II gene expression by stabilizing the class II transactivator. Journal of Cell Biology, 2012, 199, 49-63.	2.3	54
86	MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle, 2012, 11, 1593-1602.	1.3	48
87	Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress. Journal of Molecular Cell Biology, 2012, 4, 284-293.	1.5	70
88	Acetylation and sumoylation control STAT5 activation antagonistically. Jak-stat, 2012, 1, 203-207.	2.2	12
89	Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells. Clinical Cancer Research, 2012, 18, 417-431.	3.2	38
90	Breakdown of the FLT3-ITD/STAT5 Axis and Synergistic Apoptosis Induction by the Histone Deacetylase Inhibitor Panobinostat and FLT3-Specific Inhibitors. Molecular Cancer Therapeutics, 2012, 11, 2373-2383.	1.9	35

#	Article	IF	Citations
91	Differential regulation of PMLâ€“RARÎ± stability by the ubiquitin ligases SIAH1/SIAH2 and TRIAD1. International Journal of Biochemistry and Cell Biology, 2012, 44, 132-138.	1.2	23
92	Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. Cell Cycle, 2012, 11, 3219-3226.	1.3	25
93	Acetylation modulates the STAT signaling code. Cytokine and Growth Factor Reviews, 2012, 23, 293-305.	3.2	79
94	Histone deacetylase inhibitors block IFNÎ³-induced STAT1 phosphorylation. Cellular Signalling, 2012, 24, 1453-1460.	1.7	47
95	Overexpression of the Catalytically Impaired Taspase1T234V or Taspase1D233A Variants Does Not Have a Dominant Negative Effect in T(4;11) Leukemia Cells. PLoS ONE, 2012, 7, e34142.	1.1	11
96	A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. Oncotarget, 2012, 3, 31-43.	0.8	60
97	The Importinâ€Alpha/Nucleophosmin Switch Controls Taspase1 Protease Function. Traffic, 2011, 12, 703-714.	1.3	32
98	NFÎºB/p53 crosstalkâ€”a promising new therapeutic target. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1815, 90-103.	3.3	61
99	Acetylation as a Transcriptional Control Mechanismâ€”HDACs and HATs in Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Cancer, 2011, 42, 85-92.	0.6	37
100	Cell-based Analysis of Structure-Function Activity of Threonine Aspartase 1. Journal of Biological Chemistry, 2011, 286, 3007-3017.	1.6	45
101	Targeting histone deacetylases in pancreatic ductal adenocarcinoma. Journal of Cellular and Molecular Medicine, 2010, 14, 1255-1263.	1.6	27
102	Phosphorylationâ€“acetylation switch in the regulation of STAT1 signaling. Molecular and Cellular Endocrinology, 2010, 315, 40-48.	1.6	87
103	A phosphorylation-acetylation switch regulates STAT1 signaling. Genes and Development, 2009, 23, 223-235.	2.7	227
104	Histone deacetylases: salesmen and customers in the postâ€translational modification market. Biology of the Cell, 2009, 101, 193-205.	0.7	97
105	Acetylation of non-histone proteins modulates cellular signalling at multiple levels. International Journal of Biochemistry and Cell Biology, 2009, 41, 185-198.	1.2	613
106	HDACi â€“ Targets beyond chromatin. Cancer Letters, 2009, 280, 160-167.	3.2	146
107	HDAC2: a critical factor in health and disease. Trends in Pharmacological Sciences, 2009, 30, 647-655.	4.0	133
108	Mechanism for ubiquitylation of the leukemia fusion proteins AML1â€ETO and PMLâ€RARÎ±. FASEB Journal, 2008, 22, 1369-1379.	0.2	74

#	Article	IF	Citations
109	Nuclear export is essential for the tumorâ€promoting activity of survivin. FASEB Journal, 2007, 21, 207-216.	0.2	116
110	Pharmacodynamic markers for histone deacetylase inhibitor development. Drug Discovery Today Disease Mechanisms, 2007, 4, 277-283.	0.8	9
111	Acetylation of Stat1 modulates NF-ÂB activity. Genes and Development, 2006, 20, 473-485.	2.7	189
112	Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer, 2005, 104, 2717-2725.	2.0	164
113	The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO Journal, 2003, 22, 3411-3420.	3.5	460
114	Histone deacetylase as a therapeutic target. Trends in Endocrinology and Metabolism, 2001, 12, 294-300.	3.1	238